|
Advertisement |
|
|
||
 |
|
|||||
|
|||||
|
 |
||||||
|
||||||
|
||||||
|
© 2000 American Society for Clinical Oncology Survival in Early Breast Cancer Patients Is Favorably Influenced by a Natural Humoral Immune Response to Polymorphic Epithelial MucinFrom the Departments of Obstetrics and Gynecology, Clinical Chemistry, Pathology, and Surgery, Academic Hospital Vrije Universiteit, Amsterdam; and Department of Surgery, Zuiderziekenhuis, Rotterdam, the Netherlands. Address reprint requests to Silvia von Mensdorff-Pouilly, MD, Department of Obstetrics and Gynecology, Academic Hospital Vrije Universiteit, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands; email s.vonmensdorff{at}azvu.nl
PURPOSE: Polymorphic epithelial mucin (PEM or MUC1) is being studied as a vaccine substrate for the immunotherapy of patients with adenocarcinoma. The present study analyzes the incidence of naturally occurring MUC1 antibodies in early breast cancer patients and relates the presence of these antibodies in pretreatment serum to outcome of disease. MATERIALS AND METHODS: We measured immunoglobulin G (IgG) and immunoglobulin M (IgM) antibodies to MUC1 with an enzyme-linked immunoassay (PEM.CIg), which uses a MUC1 triple-tandem repeat peptide conjugated to bovine serum albumin, in pretreatment serum samples obtained from 154 breast cancer patients (52 with stage I disease and 102 with stage II) and 302 controls. The median disease-specific survival time of breast cancer patients was 74 months (range, 15 to 118 months). A positive test result was defined as MUC1 IgG or IgM antibody levels equal to or greater than the corresponding rounded-up median results obtained in the total breast cancer population. RESULTS: A positive test result for both MUC1 IgG and IgM antibodies in pretreatment serum was associated with a significant benefit in disease-specific survival in stage I and II (P = .0116) breast cancer patients. Positive IgG and IgM MUC1 antibody levels had significant additional prognostic value to stage (P = .0437) in multivariate analysis. Disease-free survival probability did not differ significantly. However, stage II patients who tested positive for MUC1 IgG and IgM antibody and who relapsed had predominantly local recurrences or contralateral disease, as opposed to recurrences at distant sites in the patients with a negative humoral response (P = .026). CONCLUSION: Early breast cancer patients with a natural humoral response to MUC1 have a higher probability of freedom from distant failure and a better disease-specific survival. MUC1 antibodies may control hematogenic tumor dissemination and outgrowth by aiding the destruction of circulating or seeded MUC1-expressing tumor cells. Vaccination of breast cancer patients with MUC1-derived (glyco)peptides in an adjuvant setting may favorably influence the outcome of disease.
POLYMORPHIC EPITHELIAL mucin (PEM or MUC1),1-4 which is expressed by most epithelial cancers,5 is attracting increasing interest as a target for the immunotherapy of adenocarcinomas,6 and several MUC1-based vaccines have already been tested in phase I clinical trials.7-10 As MUC1 is a cancer-associated circulating antigen, MUC1 serum assays, such as CA 15.3,11,12 are used in breast cancer patients to monitor therapy and, during follow-up, for early detection of recurrence.13 The MUC1 gene is located on chromosome 1q21-24.14-16 The mucin encoded by it is a high-molecular-weight (> 400 kd) transmembrane glycoprotein that is expressed at the apical cell surface of normal glandular epithelia and overexpressed in epithelial cancers (see review in Patton et al17). MUC1 expression reduces intercellular adhesion18 and participates in epithelial sheet differentiation and lumen formation during organogenesis19; it has lubricating properties and is thought to shield the mucosa from pathogens.18 The extracellular domain of the molecule consists largely of an extended highly glycosylated protein backbone that towers 200 to 500 nm above the plasma membrane18 and all other cell-surface molecules. The backbone is formed mainly of numerous tandemly bound peptide repeats with a highly conserved sequence of 20 amino acids.20-23 Each repeat has five sites, which are O-linked glycosylated in the mature MUC1 mucin molecule.24 In cancer cells, MUC1 not only loses apical distribution, becoming expressed on the whole cell surface, but is also less and aberrantly glycosylated.23-26 Truncated carbohydrate side chains, which are in themselves tumor antigens,27 result in the exposure of numerous repetitive cryptic peptide epitopes on the core protein of the molecule.23 In cancer patients, this altered molecule is shed into the circulation, comes into contact with the immune system, and originates cellular28-30 and humoral31-37 immune responses. Cytotoxic T cells that recognize MUC1 core peptides and mediate lysis of tumor targets in vitro have been obtained from patients with breast, pancreatic, and ovarian carcinomas.28-30 Agrawal et al38 demonstrated the presence of T cells that specifically proliferate in response to MUC1 in multiparous, but not in nulliparous, women. MUC1 peptide–specific major histocompatability complex class I–restricted cytotoxic T lymphocytes have been generated in vitro using T cells from multiparous women stimulated with synthetic MUC1 peptide–loaded, autologous antigen-presenting cells.39 As with the cellular immune responses, humoral immune responses are not restricted to patients with a malignant tumor but are also found in physiologic and benign situations. MUC1 antibodies that are directed to the peptide core of the molecule have been described in ulcerative colitis.31 Circulating MUC1 immunoglobulin M (IgM) antibodies are present in patients with breast, colon, and pancreatic cancer,32 in healthy women, and in patients with benign and malignant ovarian tumors.35 B cells from tumor-draining lymph nodes of ovarian cancer patients produce antibodies that react with the MUC1 protein core.33,34,36 Recently, circulating MUC1 immunoglobulin G (IgG) antibodies have been detected in patients with colorectal cancer.40 Previously, we developed an assay for the measurement of circulating MUC1 immune complexes41 and obtained preliminary results suggesting that circulating immune complexes that contain MUC1 are related to a favorable disease outcome in breast cancer patients.42 Recently, we developed an assay for the measurement of unbound circulating MUC1 IgG and IgM antibodies that are directed to the peptide core of the molecule.43 The objective of the present study was to analyze the incidence of these naturally occurring MUC1 antibodies in healthy subjects and in patients with benign and malignant breast tumors and to relate their presence in pretreatment serum to overall and disease-free survival in breast cancer patients.
The study was performed retrospectively using a total of 456 serum samples from healthy individuals and from patients with benign and malignant breast tumors.
Breast Cancer Patients
Information on patient outcome was available in all but six patients, who were treated as censored observations. The principal events analyzed were recurrence and death from breast cancer. Disease-free survival was defined as the time elapsed between the start of primary treatment and the first reappearance of breast cancer at any site (local, contralateral, or distant) (Table 1). Freedom from distant failure was defined as the time elapsed between primary treatment and the first confirmed distant metastasis. Disease-specific survival was defined as the time elapsed between primary treatment and death from breast cancer (Table 1). Five patients died of unrelated causes, four were free of recurrence, and one showed no evidence of disease after surgical treatment of a local recurrence; these patients were treated as censored observations. Five-year disease-specific survival was analyzed in patients (n = 122) who were followed-up for at least 5 years since primary treatment (n = 106) and in patients who died from breast cancer within 5 years since primary treatment (n = 16).
Control Study Population Serum samples were collected, aliquoted, and stored at -70°C until analyzed.
MUC1 Antibody Assay (PEM.CIg)
MUC1 Serum Levels
Immunohistochemistry
Statistical Methods
MUC1 was overexpressed in all 25 primary tumors stained with MAb 115D8.
Assay Results
Median MUC1 IgG and IgM levels were not substantially different in the total control population and the breast cancer patients. Median MUC1 IgG and IgM levels in the total breast cancer population were 0.646 OD (range, 0.328 to 1.514 OD) and 0.778 OD (range, 0.178 to 1.655 OD), respectively (Table 2). On the basis of these results, MUC1 IgG and IgM antibody levels  0.7 OD and 0.8 OD, respectively, were arbitrarily defined as positive. Individuals with concomitantly positive MUC1 IgG and MUC1 IgM test results (Table 2) were defined as being MUC1 antibody-positive; conversely, those with negative MUC1 IgG or negative MUC1 IgM antibody levels were defined as MUC1 antibody-negative. The number of MUC1 antibody–positive individuals was significantly higher in benign breast tumor patients than in nulligravidae (P = .038) and pregnant women (P = .003) and was significantly higher in healthy women than in pregnant women (P = .013). The number of breast cancer patients with MUC1 antibody–positive test results was significantly higher than that found in the total control population (P = .006), in nulligravidae (P = .015), and in pregnant women (P = .002). The number of breast cancer patients with MUC1 antibody–positive test results did not differ significantly between lobular and ductal carcinomas, between histologic grade 1, 2, and 3, between ER-positive and ER-negative tumors, between MAI less than or 10, nor between stage I and II.
Disease-Specific Survival
Survival analysis in relation to stage is shown in Fig 1. Probability of survival was significantly higher for pT1 in comparison to pT2 node-negative patients (P = .0261). None of the patients with lobular adenocarcinomas, and likewise none of the patients with grade 1 tumors died during the observation period. No relation was found between ER status and disease-specific survival. Patients with MAI less than 10 had a higher probability of disease-specific survival (P = .0179) than patients with MAI
A positive MUC1 IgM antibody test in pretreatment serum had, by itself, no impact on disease-specific survival. A benefit in disease-specific survival was found in patients with node-positive disease (P = .0444) and stage II disease (P = .0738) and in patients with stage I and II disease (P = .0508) in addition to a positive MUC1 IgG antibody test. Thirty-seven breast cancer patients (24%) had a MUC1 antibody–positive test result (ie, a concomitant elevation of MUC1 IgG and IgM antibodies in pretreatment serum); none died of breast cancer during the observation period. Results from Kaplan-Meier analyses for disease-specific survival and 5-year disease-specific survival as well as for disease-free survival and freedom from distant failure in relation to MUC1 antibody test results are listed in Table 3. In patients with stage I and II disease, when regarded as one group (Fig 2), probability of survival for MUC1 antibody–negative patients was 80%; at the time of analysis, no deaths from breast cancer had occurred among the MUC1 antibody–positive patients (P = .0116). A significant benefit in disease-specific survival was also observed in MUC1 antibody–positive breast cancer patients with stage II disease (Fig 3), also after adjustment for histologic grade (P = .0233), ER (P = .0205), MAI (P = .05), and nodal involvement (P = .0244). The disease-specific survival benefit that was observed in patients with stage I disease was not significant.
Five-Year Disease-Specific Survival Five-year disease-specific survival analysis could be performed in 122 patients (Table 3). Probability of survival was significantly higher for patients with stage I disease as compared with patients with stage II disease (P = .0207). MUC1 antibody–positive patients had a significantly higher probability of survival (P = .0343) than MUC1 antibody–negative patients. A benefit in survival for MUC1 antibody–positive patients (P = .0542) was also observed in patients with stage II disease (n = 83).
Disease-Free Survival
Freedom From Distant Failure Multivariate analysis showed stage to be the only independent variables (P = .0085) for prediction of freedom from distant failure in the study population. A MUC1 antibody–positive test result was associated with a lower, albeit not significant, RR for distant metastases (P = .1301; RR, 0.44; 95% CI, 0.15 to 1.28).
Kaplan-Meier analysis showed a significantly higher probability of freedom from distant failure in patients with stage I than in stage II disease (P = .0041) and in patients with MAI less than 10 than patients with MAI
Free, natural MUC1 antibodies are present in the circulation of healthy subjects as well as in cancer patients. Pregnancy and lactation, as well as inflammation of glandular epithelial tissues and tissular disarray associated with benign diseases, are physiologic and benign situations that can lead to a transitory escape to the circulation of MUC1 glycoforms and induce immune responses. In our study, nulliparous women had significantly lower absolute levels of MUC1 IgG antibodies than all other groups studied. The low MUC1 IgM levels observed in pregnant women may be due to the relative immunosuppression that is associated with pregnancy. As cellular immune responses to MUC1 have been described in multiparous women38,39 who have necessarily undergone changes in the mammary gland in preparation for lactation, the possible participation of lactation in unleashing this immune response should be investigated. It is attractive to link these observations with those obtained from epidemiologic studies indicating that nulliparity as well as an older age at first delivery increase the lifetime risk of breast cancer, whereas high parity47 and prolonged breast feeding seem to reduce the risk of breast cancer.48 Although it can be explained otherwise,49 the observed association could suggest a role of MUC1 immune responses in the immune surveillance of breast cancer. In this retrospective study, we have found a benefit in disease-specific survival in patients with stage II breast cancer who have above-median levels of circulating MUC1 IgG and IgM antibodies; however, such a benefit was not observed in disease-free survival. This disease-specific survival benefit could result from a control of disease spreading, as manifested in a lower frequency of distant metastases in MUC1 antibody–positive patients. The fact that the benefit in survival that was observed in stage I MUC1 antibody–positive patients did not reach significance may be due to the small number of patients included in the study. Studies have shown that isolated disseminated tumor cells can be found at the time of primary surgery in the bone marrow of 30% of lymph node-negative breast cancer patients50 and that their presence is associated with reduced distant disease-free survival and disease-specific survival.50,51 Antibodies may be effective in eradicating these circulating tumor cells while exerting a limited effect against the primary tumor.52,53 Unlike the primary tumor, tumor cells reach the circulation as a single cell or small clumps and are therefore highly accessible and more vulnerable to destruction. Taking this further than the classical mechanism of action of antibodies (ie, antibody-dependent cell-mediated cytotoxicity and complement-mediated lysis), antibodies to MUC1 could be involved in restoring cell adhesion, uncovering cell surface receptors involved in immune recognition, and neutralizing the immunosuppressive effect of soluble MUC1. Cell adhesion and antiadhesion are required for tumor invasion to occur, and MUC1 seems to play a role in both of these aspects.18,54 The extracellular domain of the molecule extends high above the plasma membrane,18 shielding the cancer cell and towering above other cell-surface molecules, such as those involved in cell-cell adhesive interactions55 and in immune recognition.56 Steric hindrance by MUC1 strongly decreases cell-cell57 and cell-matrix interactions and prevents epithelial cell aggregation by interfering with integrin-mediated adhesion,55 favoring invasion of tumor cells into the underlying stroma, lymph, and blood vessels.58 As is the case with monoclonal antibodies to the MUC1 repeat domain,55 antibodies that are bound to MUC1 could lead to a capping or clustering of MUC1 on the cell surface, restoring cell adhesion and limiting cancer invasion. A redistribution of MUC1 could also be instrumental in unmasking cell surface antigens that are involved in immune recognition processes56 and enabling recognition and destruction of the tumor cell by cellular effectors of the immune system. The benefit in survival observed in patients with stage I and II disease and positive levels of MUC1 IgG antibodies could be signalling the presence of a MUC1 specific T-helper lymphocyte response. This possibility is strengthened by our recent results that indicate a predominance of IgG2 subclass in these responses. On the other hand, the effectors do not necessarily have to be specific T cells, at an early tumor stage, immune surveillance and checking disease spread could be achieved by the broadly reactive properties of natural killer cells.59 MUC1 seems to be a ligand for the intercellular adhesion molecule 1 (ICAM-1), a member of the immunoglobulin superfamily.60-62 Adhesion of cancer cells to E-selectin and ICAM-1 on the cell surface of activated fibroblasts and endothelial cells could favor migration of cancer cells away from the tumor site and into the circulation. Cancer cells in the bloodstream could then, by the same mechanism, adhere to the endothelium, extravasate, and metastasize. The counter-receptor to ICAM-1 is the lymphocyte function-associated antigen (LFA-1), a member of the integrin family that is required for a broad range of leukocyte functions, including T-cell–mediated killing, T-helper responses, and B-lymphocyte responses.63 The finding that soluble MUC1 inhibits adhesion of MUC1-expressing cells to ICAM-160 and to E-selectin64 suggests an immunosuppressive role61,65,66 for the high levels of circulating mucin that are often found in patients with advanced stage disease. Furthermore, recent studies have shown expression of MUC1 on activated T cells67 as well as on normal B cells,68 which suggests that the molecule may be involved in immune modulation. The benefit in survival that was observed in the group of patients with MUC1 IgG and IgM responses could define the subset of patients with an effective primary IgM response.69 It may be that these IgM antibodies that lead to a maturation of the immune response are the ones capable of sufficiently complexing with the mucin to mediate some of the effects mentioned or, by blocking binding sites on the mucin molecule, counteract its immunosuppressive action. More than one epitope is involved in these immune responses (unpublished observations); definition of their significance in restraining tumor progression will help define the best vaccination material. In conclusion, these preliminary results seem to indicate that naturally occurring MUC1 antibodies may check disease spread in patients with breast cancer, possibly by destroying circulating or seeded isolated disseminated tumor cells (micrometastases) that eventually could lead to metastatic disease and death. Vaccination of breast cancer patients with MUC1-derived (glyco)peptides after (or even before) primary surgery could in an adjuvant setting engender immune responses that may favorably influence outcome of disease. The stronger immune response and the immunologic memory that are associated with active immunotherapy would provide a constant surveillance mechanism to protect cancer patients from recurrence of disease. A word of caution is necessary, taking into account the retrospective nature of this study. We are in the process of validating these preliminary results in a prospective study of breast cancer patients that analyzes levels of MUC1 antibodies in pretreatment serum, the detection of isolated disseminated tumor cells in the bone marrow at primary surgery, pretreatment immunologic status, and response to treatment in relation to outcome of disease.
Supported in part by a grant from the Dutch Cancer Society (KWF grant no. VU96-1318), the Biocare Foundation (grant no. 94-23), and a European Communities Concerted Action (contract no. BMH1-CT94-1462). We thank K. van Uffelen and M.J.J. Poort-Keesom for expert technical assistance.
1. Ceriani RL, Thompson K, Peterson JA, et al: Surface differentiation antigens of human mammary epithelial cells carried on the human milk fat globule. Proc Natl Acad Sci U S A 74:582-586, 1977 2. Taylor-Papadimitriou J, Peterson J, Arklie J, et al: Monoclonal antibodies to epithelium specific components of the human milk fat globule membrane: Production and reaction with cells in culture. Int J Cancer 28:17-21, 1981[Medline] 3. Hilkens J, Buijs F, Hilgers J, et al: Monoclonal antibodies prepared against human milk-fat globule membranes detecting differentiation antigens of the mammary gland and its tumors. Int J Cancer 34:197-206, 1984[Medline] 4. Kufe D, Inghirami G, Abe M, et al: Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. Hybridoma 3:223-231, 1984[Medline] 5. Zotter S, Hageman PC, Lossnitzer A, et al: Tissue and tumor distribution of human polymorphic epithelial mucin. Cancer Rev 11-12:55-101, 1988 6. Finn OJ, Jerome KR, Henderson RA, et al: MUC-1 epithelial tumor mucin-based immunity and cancer vaccines. Immunol Rev 145:61-89, 1995[Medline] 7. Goydos JS, Elder E, Whiteside TL, et al: A phase I trial of a synthetic mucin peptide vaccine induction of specific immune reactivity in patients with adenocarcinoma. J Surg Res 63:298-304, 1996[Medline] 8. Xing PX, Michael M, Apostolopoulos V, et al: Phase I study of synthetic MUC1 peptides in breast cancer. Int J Oncol 6:1283-1289, 1995 9. Karanikas V, Hwang LA, Pearson J, et al: Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. J Clin Invest 100:2783-2792, 1997[Medline] 10. Reddish MA, MacLean GD, Koganty RR, et al: Anti-MUC1 class I restricted CTLs in metastatic breast cancer immunized with a synthetic MUC1 peptide. Int J Cancer 76:817-823, 1998[Medline] 11. Hayes DF, Sekine H, Ohno T, et al: Use of a murine monoclonal antibody for detection of circulating plasma DF3 antigen levels in breast cancer patients. J Clin Invest 75:1671-1678, 1985
12.
Bon GG, von Mensdorff-Pouilly S, Kenemans P, et al: Clinical and technical evaluation of ACS BR serum assay of MUC1 gene-derived glycoprotein in breast cancer, and comparison with CA 15-3 assays. Clin Chem 43:585-593, 1997 13. Graves R, Hilgers J, Fritsche H, et al: MUC-1 mucin assays for monitoring therapy in metastatic breast cancer. Breast 7:181-186, 1998
14.
Gendler SJ, Burchell JM, Duhig T, et al: Cloning of partial cDNA encoding differentiation and tumor-associated mucin glycoproteins expressed by human mammary epithelium. Proc Natl Acad Sci U S A 84:6060-6064, 1987 15. Swallow D, Gendler S, Griffiths B, et al: The hypervariable gene locus PUM, which codes for the tumor-associated epithelial mucins, is located on chromosome 1 within the region 1q21-24. Ann Hum Genet 51:289-294, 1987[Medline]
16.
Siddiqui J, Abe M, Hayes D, et al: Isolation and sequencing of a cDNA coding for the human DF3 breast carcinoma-associated antigen. Proc Natl Acad Sci U S A 85:2320-2323, 1988 17. Patton S, Gendler SJ, Spicer AP: The epithelial mucin, MUC1, of milk, mammary gland and other tissues [review]. Biochim Biophys Acta 1241:407-423, 1995[Medline] 18. Hilkens J, Ligtenberg JL, Vos HL, et al: Cell membrane-associated mucins and their adhesion-modulating property. Sci 17:359-363, 1992 19. Braga VMM, Pemberton LF, Duhig T, et al: Spatial and temporal expression of an epithelial mucin, Muc-1, during mouse development. Development 115:427-437, 1992[Abstract]
20.
Gendler SJ, Lancaster CA, Taylor-Papadimitriou J, et al: Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. J Biol Chem 265:15286-15293, 1990
21.
Ligtenberg MJL, Vos B, Gennissen A, et al: Episialin, a carcinoma-associated mucin, is generated by a polymorphic gene encoding splice variants with alternative amino termini. J Biol Chem 265:5573-5578, 1990 22. Price MR, Hudezc F, O’Sullivan C, et al: Immunological and structural features of the protein core of human polymorphic epithelial mucin. Mol Immunol 27:795-802, 1990[Medline] 23. Burchell J, Taylor-Papadimitriou J: Effect of modification of carbohydrate side chains on the reactivity of antibodies with core-protein epitopes of the MUC1 gene product. Cell Biol 2:155-162, 1993
24.
Müller S, Goletz S, Packer N, et al: Localization of O-glycosylation sites on glycopeptide fragments from lactation-associated MUC1. J Biol Chem 272:24780-24793, 1997 25. Brockhausen I, Yang JM, Burchell J, et al: Mechanisms underlying aberrant glycosylation of MUC1 mucin in breast cancer cells. Eur J Biochem 233:607-618, 1995[Medline]
26.
Whitehouse C, Burchell J, Gschmeissner S, et al: A transfected sialyltransferase that is elevated in breast cancer and localizes to the medial/trans-Golgi apparatus inhibits the development of core-2-based O-glycans. J Cell Biol 137:1229-1241, 1997 27. Zhang S, Zhang HS, Gordon-Cardo C, et al: Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group-related antigens. Int J Cancer 73:50-56, 1997[Medline]
28.
Jerome KR, Barnd DL, Bendt KM, et al: Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res 51:2908-2916, 1991 29. Jerome KR, Domenech N, Finn OJ: Tumor-specific cytotoxic T cell clones from patients with breast and pancreatic adenocarcinoma recognize EBV-immortalized B cells transfected with polymorphic epithelial mucin complementary DNA. J Immunol 151:1654-1662, 1993[Abstract] 30. Ionnanides CG, Fisk B, Jerome KR, et al: Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides. J Immunol 151:3693-3703, 1993[Abstract] 31. Hinoda Y, Nakagawa N, Nakamura H, et al: Detection of a circulating antibody against a peptide epitope on a mucin core protein, MUC1, in ulcerative colitis. Immunol Lett 35:163-168, 1993[Medline]
32.
Kotera Y, Fontenot DJ, Pecher G, et al: Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients. Cancer Res 54:2856-2860, 1994
33.
Rughetti A, Turchi V, Ghetti CA, et al: Human B-cell immune response to the polymorphic epithelial mucin. Cancer Res 53:2457-2459, 1993 34. Petrarca C, Rughetti A, Rahimi H, et al: Human antibodies against polymorphic epithelial mucin in ovarian cancer patients recognize a novel sequence in the tandem repeat region. Eur J Cancer 32A:2155-2163, 1996 35. Richards ER, Devine PL, Quin RJ, et al: Antibodies reactive with the protein core of MUC1 mucin are present in ovarian cancer patients and healthy women. Cancer Immunol Immunother 46:245-252, 1998[Medline] 36. Petrarca C, Casalino B, von Mensdorff-Pouilly S, et al: Isolation of MUC1-primed B lymphocytes from tumor-draining lymph nodes by immunomagnetic beads. Cancer Immunol Immunother 47:272-277, 1999[Medline] 37. Henderikx P, Kandilogiannaki M, Petrarca C, et al: Human single-chain Fv antibodies to MUC1 core peptide selected from phage display libraries recognize unique epitopes and predominantly bind adenocarcinoma. Res 58:4324-4332, 1998
38.
Agrawal B, Reddish MA, Krantz MJ, et al: Does pregnancy immunize against breast cancer? Cancer Res 55:2257-2261, 1995 39. Agrawal B, Reddish MA, Longenecker BM: In vitro induction of MUC-1 peptide-specific type 1 T Lymphocyte and cytotoxic T lymphocyte responses from healthy multiparous donors. Immunol 157:2089-2095, 1996 40. Nakamura H, Hinoda Y, Nakagawa N, et al: Detection of circulating anti-MUC1 mucin core protein antibodies in patients with colorectal cancer. J Gastroenterol 33:354-361, 1998[Medline] 41. Gourevitch MM, von Mensdorff-Pouilly S, Litvinov SV, et al: Polymorphic epithelial mucin (MUC-1)-containing circulating immune complexes in carcinoma patients. Br J Cancer 72:934-938, 1995[Medline] 42. von Mensdorff-Pouilly S, Gourevitch MM, Kenemans P, et al: Humoral immune response to polymorphic epithelial mucin (MUC-1) in patients with benign and malignant breast tumours. Eur J Cancer 32A:1325-1331, 1996 43. von Mensdorff-Pouilly S, Gourevitch MM, Kenemans P, et al: An enzyme-linked immunosorbent assay for the measurement of circulating antibodies to polymorphic epithelial mucin (MUC1). Tumor Biol 19:186-195, 1998 44. van Diest PJ, Baak JPA, Matze-Cok P, et al: Reproducibility of mitosis counting in 2469 breast cancer specimens: Results from the Multicenter Morphometric Mammary Carcinoma Project. Hum Pathol 23:603-607, 1992[Medline] 45. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-220, 1972 46. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
47.
Rosner B, Colditz G, Willet W: Reproductive risk factors in a prospective study of breast cancer: The nurse’s health study. Am J Epidemiol 139:819-835, 1994
48.
Yoo KY, Tajima K, Kuroishi T, et al: Independent protective effect of lactation against breast cancer: A case control study in Japan. Am J Epidemiol 135:726-733, 1992 49. Russo J, Russo IH: Differentiation and breast cancer. Medicina (B Aires) 57:81-91, 1997 (suppl 2)
50.
Diel IJ, Kaufman M, Costa SD, et al: Micrometastatic breast cancer cells in bone marrow at primary surgery: Prognostic value in comparison with nodal status. Inst 88:1652-1664, 1996 51. Harbeck N, Untch M, Pache L, et al: Tumour cell detection in the bone marrow of breast cancer patients at primary therapy: Results of a 3-year median follow-up. Br J Cancer 69:566-571, 1994[Medline] 52. Livingston PO, Zhang S, Lloyd KO: Carbohydrate vaccines that induce antibodies against cancer: 1. Rationale. Cancer Immunol Immunother 45:1-9, 1997[Medline] 53. Livingston PO, Ragupathi G: Carbohydrate vaccines that induce antibodies against cancer: 2. Previous experience and future plans. Immunother 45:10-19, 1997
54.
Yamamoto M, Bharti A, Li Y, et al: Interaction of the DF3/MUC1 breast carcinoma associated antigen and ß-catenin in cell adhesion. J Biol Chem 272:12492-12494, 1997
55.
Wesseling J, van der Valk SW, Vos HL, et al: Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. J Cell Biol 129:255-265, 1995 56. van de Wiel-van Kemenade E, Ligtenberg MJL, de Boer AJ, et al: Episialin (MUC1) inhibits cytotoxic lymphocyte-target cell interaction. J Immunol 151:767-776, 1993[Abstract]
57.
Ligtenberg MJL, Buijs F, Vos HL, et al: Suppression of cellular aggregation by high levels of episialin. Cancer Res 52:2318-2324, 1992 58. Hiraga Y, Tanaka S, Haruma K, et al: Immunoreactive MUC1 expression at the deepest invasive portion correlates with prognosis of colorectal cancer. Oncology 55:307-319, 1998[Medline] 59. Whiteside TL, Herberman RB: The role of natural killer cells in immune surveillance of cancer. Curr Opin Immunol 7:704-710, 1995[Medline]
60.
Regimbald LH, Pilarski LM, Longenecker BM, et al: The breast mucin MUC1 as a novel adhesion ligand for endothelial intercellular adhesion molecule 1 in breast cancer. Cancer Res 56:4244-4249, 1996 61. Agrawal B, Krantz MJ, Reddish MA, et al: Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by Il-2. Nat Med 4:43-49, 1998[Medline]
62.
Kam JL, Regimbald LH, Hilgers JH, et al: MUC1 synthetic peptide inhibition of intercellular adhesion molecule-1 and MUC1 binding requires six tandem repeats. Cancer Res 58:5577-5581, 1998 63. Springer TA: Adhesion receptors of the immune system. Nature 346:425-434, 1990[Medline] 64. Zhang K, Baeckström D, Hansson GC: A secreted mucin carrying sialyl-Lewis a from colon carcinoma cells binds to E selectin and inhibits HL-60 cell adhesion. Int J Cancer 59:823-829, 1994[Medline] 65. Zhang K, Sikut R, Hansson GC: A MUC1 mucin secreted from a colon carcinoma cell line inhibits target cell lysis by natural killer cells. Cell Immunol 176:158-165, 1997[Medline] 66. Snijdewint FGM, von Mensdorff-Pouilly S, Karuntu-Wanamarta AH, et al: Cellular and humoral responses to MUC1 mucin and tandem-repeat peptides in ovarian cancer patients and controls. Cancer Immunol Immunother 48:47-55, 1999[Medline]
67.
Agrawal B, Krantz MJ, Parker J, et al: Expression of MUC1 mucin on activated human T cells: Implication for a role of MUC1 in normal immune regulation. Cancer Res 58:4079-4081, 1998
68.
Treon SP, Mollick JA, Urashima M, et al: MUC1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone. Blood 93:1287-1298, 1999
69.
Ehrenstein MR, O’Keefe TL, Davies SL, et al: Targeted gene disruption reveals a role for natural secretory IgM in the maturation of the primary immune response. Proc Natl Acad Sci U S A 95:10089-10093, 1998 Submitted March 1, 1999; accepted October 5, 1999.
This article has been cited by other articles:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||||||||||
|
|||||||||||
|
|
Copyright © 2000 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
|
TOP
ABSTRACT
INTRODUCTION
2 test or, when the sample size was small, a Fisher’s exact test. Multivariate analysis of disease-specific survival, disease-free survival, and freedom from distant failure was performed using the Cox proportional hazards regression model.
